Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu; Masataka Okamoto; Hirokazu Nakamine; Masami Hirano

doi:10.1016/j.leukres.2008.04.005

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

Original language	English
Pages (from-to)	1837-1841
Number of pages	5
Journal	Leukemia Research
Volume	32
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2008.04.005
Publication status	Published - 01-12-2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2008.04.005

Fingerprint Dive into the research topics of 'Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this

@article{92d22cef1a954dcf9b52697fef5da411,

title = "Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma",

abstract = "We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.",

author = "Nozomi Niitsu and Masataka Okamoto and Hirokazu Nakamine and Masami Hirano",

year = "2008",

month = dec,

day = "1",

doi = "10.1016/j.leukres.2008.04.005",

language = "English",

volume = "32",

pages = "1837--1841",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

AU - Niitsu, Nozomi

AU - Okamoto, Masataka

AU - Nakamine, Hirokazu

AU - Hirano, Masami

PY - 2008/12/1

Y1 - 2008/12/1

N2 - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

AB - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

UR - http://www.scopus.com/inward/record.url?scp=51649089821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649089821&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.04.005

DO - 10.1016/j.leukres.2008.04.005

M3 - Article

C2 - 18490056

AN - SCOPUS:51649089821

VL - 32

SP - 1837

EP - 1841

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -